个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Li, Jin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] * ; Wang, Zhi-Qiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhong, Haijun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; He, Yifu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Chen[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Niu, Zuoxing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Yang, Shujun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Tao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhu, Liangjun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Shu, Yongqian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Peng, Jianjun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Song, Yan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Li, Jian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Yuan, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Haibo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Yu, Gengsheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Hua, Yun-Qi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Xiao, Jianjun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Shi, Michael[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Su, Weiguo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ;
机构： [1]Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China [2]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr,Dept Med Oncol, Guangzhou, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Peoples R China [4]Anhui Prov Canc Hosp, Dept Med Oncol, Hefei, Anhui, Peoples R China [5]Ningbo 2 Hosp, Dept Radiotherapy & Chemotherapy, Ningbo, Peoples R China [6]Shandong Canc Hosp, Dept Gastroenterol, Jinan, Peoples R China [7]Henan Canc Hosp, Zhengzhou, Peoples R China [8]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China [9]Jiangsu Canc Hosp, Nanjing, Peoples R China [10]Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China [11]Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Peoples R China [12]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Med Oncol,Canc Hosp, Beijing, Peoples R China [13]Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [14]Zhejiang Univ, Sch Med, Dept Med Oncol, Affiliated Hosp 2, Hangzhou, Peoples R China [15]Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China [16]Jiangmen Cent Hosp, Dept Med Oncol, Jiangmen, Peoples R China [17]Baotou Tumor Hosp, Dept Chemotherapy, Baotou, Peoples R China [18]Zhongshan City Peoples Hosp, Dept Oncol, Zhongshan, Peoples R China [19]HUTCHMED Ltd, Shanghai, Peoples R China
出处：
ISSN：
基金：
HUTCHMED Limited
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China [2]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr,Dept Med Oncol, Guangzhou, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Peoples R China [4]Anhui Prov Canc Hosp, Dept Med Oncol, Hefei, Anhui, Peoples R China [5]Ningbo 2 Hosp, Dept Radiotherapy & Chemotherapy, Ningbo, Peoples R China [6]Shandong Canc Hosp, Dept Gastroenterol, Jinan, Peoples R China [7]Henan Canc Hosp, Zhengzhou, Peoples R China [8]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China [9]Jiangsu Canc Hosp, Nanjing, Peoples R China [10]Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China [11]Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Peoples R China [12]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Med Oncol,Canc Hosp, Beijing, Peoples R China [13]Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [14]Zhejiang Univ, Sch Med, Dept Med Oncol, Affiliated Hosp 2, Hangzhou, Peoples R China [15]Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China [16]Jiangmen Cent Hosp, Dept Med Oncol, Jiangmen, Peoples R China [17]Baotou Tumor Hosp, Dept Chemotherapy, Baotou, Peoples R China [18]Zhongshan City Peoples Hosp, Dept Oncol, Zhongshan, Peoples R China [19]HUTCHMED Ltd, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Li Jin,Wang Zhi-Qiang,Zhong Haijun,et al.A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Li, Jin,Wang, Zhi-Qiang,Zhong, Haijun,He, Yifu,Zhang, Chen...&Su, Weiguo.(2023).A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Li, Jin,et al."A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号